CEREBRAL STATE MONITOR - CSM

K042315 · Danmeter A/S · OLW · Jan 21, 2005 · Neurology

Device Facts

Record IDK042315
Device NameCEREBRAL STATE MONITOR - CSM
ApplicantDanmeter A/S
Product CodeOLW · Neurology
Decision DateJan 21, 2005
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 882.1400
Device ClassClass 2

Intended Use

The CSM monitor is intended for use in monitoring the hypnotic state of the brain by data acquisition of EEG signals of the anaesthetized or sedated patient in all areas of the hospital.

Device Story

Cerebral State Monitor (CSM) is a non-invasive EEG-based device; used by trained healthcare professionals in hospital settings to monitor level of consciousness (LOC) during general anaesthesia or sedation. Device acquires EEG signals via Danmeter Neuro Sensors; processes signals to calculate a Cerebral State Index (CSI). Output is displayed as a numerical index; device performs no clinical interpretation, which remains the responsibility of the physician. Optional accessories include PC software for data documentation, wireless link, and thermal printer. Clinical benefit involves providing objective data to assist physicians in assessing patient hypnotic state, potentially aiding in titration of anaesthetic or sedative agents.

Clinical Evidence

Bench testing only. No clinical trial data provided in the summary.

Technological Characteristics

Non-invasive EEG monitor; utilizes Danmeter Neuro Sensors for signal acquisition. Powered by 9V alkaline or rechargeable NiMH battery; optional mains power supply. Connectivity includes wireless link to host computer and PC software for data formatting. Form factor is a portable monitor. Software performs EEG signal processing to derive CSI index.

Indications for Use

Indicated for monitoring the hypnotic state of the brain in anaesthetized or sedated patients in all hospital areas.

Regulatory Classification

Identification

An electroencephalograph is a device used to measure and record the electrical activity of the patient's brain obtained by placing two or more electrodes on the head.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ JAN 2 1 2005 K 042315 ## SUMMARY OF SAFETY AND EFFECTIVENESS Cerebral State Monitor - CSM ## SUBMITTER INFORMATION | A. | Company Name: | Danmeter A/S | |----|--------------------------------|--------------------------------------------------| | B. | Company Address: | Kildemosevej 13<br>DK-5000 Odense C | | C. | Company Phone:<br>Company Fax: | +45 63 11 29 30<br>+45 63 11 29 31 | | D. | Contact Person: | Hanne Nielsen<br>Quality Manager<br>Danmeter A/S | | E. | Date Summary Prepared: | August 19, 2004 | #### DEVICE IDENTIFICATION | A. | Generic Device Name: | Electroencephalograph | |----|-------------------------|------------------------------| | B. | Trade/Proprietary Name: | Cerebral State Monitor - CSM | | C. | Classification: | Class II | | D. | Product Code: | OLW, OMC, DRT | ### SUBSTANTIAL EQUIVALENCE The Cerebral State Monitor - CSM is of comparable type and is substantially equivalent to the following predicate devices: | Predicate Device | Manufacturer | 510(k) No. | Date Cleared | |--------------------------------|------------------------------------------------------|------------|--------------| | AEP Monitor | Danmeter A/S<br>(Reg. by: Alaris<br>Medical Systems) | K010965 | 6/27/2001 | | A-2000 EEG<br>Monitor with BIS | Aspect Medical<br>Systems | K974496 | 2/6/1998 | l {1}------------------------------------------------ #### DEVICE DESCRIPTION The Cerebral State Monitor (CSM) is a non-invasive measurement tool for use by trained healthcare professionals to measure the level of consciousness (LOC) in all areas of the hospital. Based on EEG, an index (CSI) is calculated, which is used in the estimation of LOC. The CSM displays the CSI but does not perform any data interpretation (i.e., all data interpretation is performed by a physician). The following accessories are provide with the CSM: - Danmeter Neuro Sensors - 9V Alkaline battery ● - Skin preparation - Rechargeable 9V NiMH battery (Optional) . - CSM Power (Optional) Mains Power supply ● - CSM Capture (Optional) PC-SW. This software allows the physician to . format data on a PC, for documentation purposes. - CSM Link (Optional) Wireless link to RS232 to host computer . - CSM Printer (Optional) Thermal printer for documentation purposes ● #### INTENDED USE The CSM is intended for use in monitoring the state of the brain by data acquisition of EEG signals of the anaesthetized or sedated patient in all areas of the hospital. The CSM is a non-invasive measurement tool to be used by a trained professional to measure the level of consciousness during general anaesthesia or sedation by use of CSI. #### TECHNOLOGICAL CHARACTERISTICS A comparison of the technological characteristics of the Cerebral State Monitor -CSM and the predicate devices has been performed. The results of this comparison demonstrate that the Cerebral State Monitor - CSM is equivalent to the marketed predicate devices. #### PERFORMANCE DATA The performance data indicate that the Cerebral State Monitor - CSM meets all specified requirements, and is substantially equivalent to the predicate devices. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like symbol, with three curved lines forming the body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the symbol. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Mr. Hanne Nielsen Quality Manager Danmeter A/S Kildemosevej 13 DK-5000 Odense C Denmark APR - 9 2012 Re: K042315 Trade/Device Name: Cerebral State Monitor Regulation Number: 21 CFR 882.1400 Regulation Name: Electroencephalograph Regulatory Class: II Product Code: OLW, OMC, ORT Dated (Date on orig SE ltr): December 1, 2004 Received (Date on orig SE ltr): December 3, 2004 Dear Mr. Nielsen: This letter corrects our substantially equivalent letter of January 21, 2005. We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely vours. Kesia Alexander Malvina B. Eydelman, M.D. Director Division of Ophthalmic. Neurological, and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## DEVICE SPECIFICATIONS # INDICATIONS FOR USE | 510(k) Number: | K042315 (To Be Assigned by FDA) | |----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Device Name: | Cerebral State Monitor - CSM | | Indications for use: | The CSM monitor is intended for use in monitoring the<br>hypnotic state of the brain by data acquisition of EEG<br>signals of the anaesthetized or sedated patient in all areas<br>of the hospital. | (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) メ Prescription Use (Part 21 CFR 801 Subpart D) - AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) Muriam C. Provost (Division Sign-Off) Division of General, Restorative, and Neurological Devices Page 1 of _1__ 510(k) Number_________________________________________________________________________________________________________________________________________________________________
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...